This is an automatically translated article.
Invegga Sustenna has the effect of making the patient feel excited and positive. Therefore, Invega Sustenna is a drug used in the treatment of mental and emotional disorders. The drug is available in the form of an extended-release suspension for injection. To better understand the uses and indications of Invega sustenna, read the article below.
1. What are the effects of Invega Sustenna?
Invega Sustenna medicine has the main ingredient is Paliperidone (as Paliperidone palmitate) 150mg/1.5ml, an atypical antipsychotic active ingredient.
The main use of Invega Sustenna can cause hallucinations to help patients think more positively about themselves and life. Thereby reducing the anxiety of being agitated from psychotic diseases. Invega Sustenna users will also feel more active and excited in their daily activities.
Classified as atypical second-generation antipsychotics, Invega Sustenna is effective in the treatment of schizophrenia. Invenga Sustenna is used in combination with an antidepressant or a mood stabilizer in adults and adolescents. In addition to the extended-release suspension dosage form, Invega Sustenna also has a 24-hour extended-release tablet form, with Paliperidone strengths of 1.5mg, 3mg, 6mg, 9mg.
On the market today, Invega Sustenna is produced in 2 types, 100mg and 150mg, prepared as an extended-release suspension in the manufacturer's prefilled syringe. Invega Sustenna is used for adults over 18 years old and children from 12-17 years old must be supervised and prescribed by a doctor.
Invega Sustenna is only indicated in the treatment of psychotic diseases, specifically as follows.
Mental disorders/ affective disorders/ bipolar disorder Schizophrenia Support treatment of people with depression On the other hand, patients who are sensitive to paliperidone and risperidone will not be prescribed a prescription.
2. Dosage of Invega Sustenna
Dosage of Invega Sustenna is divided into extended-release tablets and extended-release suspension for infusion.
2.1. Extended-release suspension for infusion In the treatment of patients who have never received paliperidone or risperidone, oral paliperidone or risperidone must be tolerated prior to treatment with the infusion suspension. The initial dose was 234 mg/paliperidone palmitate IM on day one, followed by 156 mg IM for one week later. Intramuscular site at deltoid muscle Maintenance dose: 117 mg IM monthly. Location: injection into the deltoid muscle or buttock injection. Dosage can range from 39mg - 234mg depending on the condition and tolerance of the patient. Dosage may need to be adjusted monthly according to the doctor's prescription and evaluation. 2.2.Extended-release tablets Standard dose: 6 mg/day, taken once daily. Dose range can range from: 3-12 mg/day; Dosage increases may be about 3 mg/day and should be done over 5 days. Maximum dose: 12 mg/day. Dosage for adults with schizoaffective disorder
Recommended dose: 6 mg/day, taken once daily Dosage can be adjusted 3-12 mg/day; Dosage increases can be made within the permissible range of 3 mg/day and should be done over 4 days to be effective. Maximum dose: 12 mg/day, orally. For children 12-17 years of age, the recommended dose is 3 mg/day, orally once.
Dosage: 3-12 mg per day; Dosage increases can be made within 3 mg per day and should be done over 5 days. Maximum dose: 12 mg/day, administered orally.
3. Invega Sustenna side effects
Common side effects
Breast swelling or discharge Severe menstrual cycle changes Restlessness, tremors, cravings for sleep, dry mouth Blurred vision Dizziness with headache Decreased libido, impotence in men. Rare side effects
Muscle tension, high fever, sweating Heart rhythm disturbances, feeling of fainting Difficulty swallowing Muscle twitching in the head, face, neck and neck Weakness on one side of the body White spots or sores in the mouth Unbalanced , sudden headache and severe pain. If you have severe symptoms as mentioned above, contact a specialist or go to the nearest hospital for timely first aid.
4. Notes when using Invega Sustenna
Invega Sustenna may increase mortality in elderly (geriatric) patients with mental disorders with dementia For people with neuroleptic malignant syndrome (NMS), the risk Very high mortality has also been reported. Therefore, Invega Sustenna should not be used in these patients. For patients with mental illnesses, psychosis who have ever had suicidal thoughts, they should be prescribed the smallest appropriate dose, using the drug under the supervision of doctors and family members. For nursing women, according to reports on the secretion in breast milk of the active ingredient in the drug Invega Sustenna, there is an effect on the nursing infant. Therefore, women who are breast-feeding should not use Invega Sustenna. Invega Sustenna has been assessed to have an effect on the nervous and visual systems (euphoria, dynamics, or appetite). Therefore, people who operate machinery and drive vehicles should not take this medicine. Invega Sustenna drug with the main active ingredient is Paliperidone palmitate) is used in the treatment of psychiatric patients, psychosis, support treatment of depression in combination with some other drugs. This is a drug to be used under the supervision and prescription of a doctor, the patient must not arbitrarily use in any form.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
